James Paauw, MD
Ophthalmology · Lynchburg, VANPI 1568608966
Payments from drug & device makers
Across 2,654 payments — averaging $2639.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2.7M
- Alcon Research LLC$1.4M
- Oyster Point Pharma, Inc.$932K
- Bausch & Lomb Americas Inc.$737K
- Glaukos Corporation$526K
- Novartis$424K
- plus $327K from 15 others
Across 24 payments — averaging $7994.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beaver-visitec International, Inc.$133K
- NEW World Medical,inc.$57K
- AbbVie$2K
What the payments were for
- Consulting fees$67,58395%
- Speaking & faculty fees$5171%
- Food & beverage$3,2875%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 345 | $2,657,291 |
| Alcon Research LLC | 2,040 | $1,401,488 |
| Oyster Point Pharma, Inc. | 28 | $931,649 |
| Bausch & Lomb Americas Inc. | 25 | $736,672 |
| Glaukos Corporation | 113 | $525,683 |
| Novartis | 11 | $423,892 |
| Padagis US LLC | 5 | $123,604 |
| Aerie Pharmaceuticals, Inc. | 11 | $80,634 |
| Shire North American Group Inc | 11 | $40,596 |
| Beaver-visitec International, Inc. | 1 | $35,458 |
| Rxsight Inc | 9 | $26,283 |
| Perrigo Company PLC | 6 | $14,742 |
| Vanda Pharmaceuticals Inc. | 1 | $5,000 |
| Alcon | 35 | $769 |
| Genentech USA, Inc. | 1 | $128 |
| NEW World Medical,inc. | 4 | $89 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $47 |
| Tarsus Pharmaceuticals, Inc. | 2 | $36 |
| Thea Pharma Inc. | 1 | $25 |
| Harrow Eye, LLC | 1 | $22 |
| Ocular Therapeutix, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,004,126 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 326 | $203,995 |
| RocklatanNetarsudil Mesylat/Latanoprost | 150 | $86,839 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 150 | $53,564 |
| Travoprost | 226 | $47,168 |
| XdemvyLotilaner | 20 | $37,473 |
| ProlensaBromfenac Sodium | 93 | $32,149 |
| RestasisCyclosporine | 29 | $28,034 |
| XiidraLifitegrast | 30 | $26,199 |
| RhopressaNetarsudil Mesylate | 35 | $24,328 |
| CombiganBrimonidine Tartrate/Timolol | 58 | $23,599 |
| Latanoprost | 2,332 | $22,043 |
| Prednisolone Acetate | 667 | $21,212 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 117 | $17,093 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 738 | $14,940 |
| VyzultaLatanoprostene Bunod | 19 | $13,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $2,657,291 | $255,628413 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $80,634 | $111,167185 claims |
| AlconSimbrinza | $769 | $53,564150 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $736,672 | $40,17449 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $36 | $37,47320 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $47 | $32,14993 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $931,649 | $10,68913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Lynchburg
- Golnaz JaveyLynchburg$6.7M
- Kapil KapoorNorfolk$4.3M
- Ali TabassianRichmond$2.1M
- Elizabeth Yeu-LinNorfolk$2M
- Ethnie JonesRichmond$2M
- Alan WagnerNorfolk$1.8M
- John SheppardNorfolk$1.2M
- Gustavo CorralesFalls Church$888K
- Frank CotterRoanoke$874K
- Constance OkekeNorfolk$822K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.